Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Firategrast
GlaxoSmithKline Product Development Pipeline
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Other National MS Societies (Not listed here)
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
8th World Congress on Controversies in Neurology (CONy)
Episode 13 with Professor Alan Thompson on the International Progressive MS Alliance.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Aubagio® significantly reduced risk of new clinical relapse or MRI lesion in multiple sclerosis study
Microglia in health and disease.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
endMS CONFERENCE
“Human Medicines” page
Free MED IQ Live CME Event on Multiple Sclerosis Nov 22nd
ASNI Calgary 2015
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
JOINT CONGRESS OF EUROPEAN NEUROLOGY

Pages